SCHEMBL541560

SCHEMBL541560

O=C(c1cnc(N[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2CO)nc1C(F)(F)F)N1CCS(=O)(=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.40
SCD O00767 1/20 0.38
ALOX5AP P20292 2/20 0.34
FEN1 P39748 2/20 0.34
SYK P43405 2/20 0.33
TRPV3 Q8NET8 1/20 0.33
CNR2 P34972 8/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C19 P33261 2/20 0.33
KDR P35968 1/20 0.33
AURKB Q96GD4 1/20 0.33
CYP1A2 P05177 1/20 0.33
HSD11B1 P28845 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPK3 P27361 1/20 0.32
SCN9A Q15858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12796079 1.00 CXCR4 (0.40) CXCR4SCDALOX5APFEN1SYK
SCHEMBL541561 0.94 CXCR4 (0.40) CXCR4SCDTRPV3CNR2CYP2D6
SCHEMBL541559 0.94 CXCR4 (0.40) CXCR4SCDTRPV3CNR2CYP2D6
SCHEMBL12796620 0.91 CXCR4 (0.38) CXCR4SCDALOX5APFEN1SYK
SCHEMBL12796627 0.91 CXCR4 (0.38) CXCR4SCDALOX5APFEN1SYK
SCHEMBL12796662 0.89 CXCR4 (0.37) CXCR4SCDALOX5APFEN1SYK
SCHEMBL541570 0.84 SYK (0.43) CXCR4SCDALOX5APFEN1SYK
SCHEMBL12796694 0.84 CXCR4 (0.39) CXCR4SCDALOX5APFEN1SYK
SCHEMBL10145905 0.83 KDR (0.41) CXCR4SCDSYKKDRAURKB
SCHEMBL541084 0.83 KDR (0.41) CXCR4SCDSYKKDRAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310373-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-11-21 US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 US disclosed
EP-2415765-A1 PYRIMIDINE COMPOUND Astellas Pharma Inc. (JP) 2012-02-08 EP disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053912-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 CXCR4 350/4885SCD 1093/4885ALOX5AP 407/4885
US-20130310373-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 CXCR4 206/4885SCD 1251/4885ALOX5AP 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.